WAG
ALNY icon

Wilkerson Advisory Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Wilkerson Advisory Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.22K Sell
24
-1
-4% -$302 ﹤0.01% 463
2026
Q1 		$8.27K Buy
25
+8
+47% +$2.72K ﹤0.01% 434
2025
Q4 		$6.76K Buy
+17
New +$7.52K ﹤0.01% 398

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wilkerson Advisory Group's ALNY Position: Q2 2026 in Review

Wilkerson Advisory Group reduced its Alnylam Pharmaceuticals (ALNY) stake by 4% in Q2 2026, selling an estimated $302 and leaving 24 shares worth $7.22K. The position accounts for ﹤0.01% of the portfolio, ranked #463.

Wilkerson Advisory Group first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. The position peaked at $8.27K in Q1 2026. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Wilkerson Advisory Group held 24 shares of Alnylam Pharmaceuticals worth $7.22K as of Q2 2026.
  • Wilkerson Advisory Group sold 1 Alnylam Pharmaceuticals share in Q2 2026, an estimated $302.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Wilkerson Advisory Group's portfolio in Q2 2026, its #463 holding.
  • Wilkerson Advisory Group first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Wilkerson Advisory Group's Alnylam Pharmaceuticals position peaked at $8.27K in Q1 2026.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Wilkerson Advisory Group's 13F filing for Q2 2026, filed 21 Jul 2026.